GMO International Quality ETF
QLTI - ETF AI Analysis
Top Page
GMO International Quality ETF (QLTI)
QLTI, the GMO International Quality ETF, earns a solid overall rating driven mainly by high-quality global leaders like TSM, ASML, and Novartis, which combine strong financial performance with positive growth prospects in advanced technologies and healthcare. The fund’s score is held back somewhat by holdings where valuations look expensive or technical trends are weaker, such as SAP and L’Oreal, and by pockets of caution around diagnostics and regional challenges. A key risk factor is that many top holdings face valuation concerns and sector-specific issues, which could increase volatility if growth expectations are not met.
QLTI vs. SPDR S&P 500 ETF (SPY)
- AUM
- 289.87M
- Region
- Global Ex-U.S.
- Expense Ratio
- 0.60%
- Beta
- 0.72
- Issuer
- GMO
- Inception Date
- Oct 28, 2024
- Dividend Yield
- 0.57%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
QLTI Summary
GMO International Quality ETF (QLTI) is an actively managed fund that invests in high-quality companies from around the world, with a big portion in the U.S. It doesn’t track a specific index, but follows a “quality” theme, focusing on businesses with strong finances and steady earnings. The fund holds well-known names like TSMC and Unilever, along with leading European and Asian firms across technology, healthcare, consumer goods, and more. Someone might invest in QLTI for global diversification and long-term growth potential. A key risk is that its stock prices can rise and fall with global markets, including foreign currency and economic swings.
How much will it cost me?
This ETF has an expense ratio of 0.60%, which means you’ll pay about $6 per year for every $1,000 invested. That’s higher than the average ETF because it’s actively managed, focusing on carefully selected high-quality international companies rather than simply tracking a broad market index.
What would affect this ETF?
This global ex-U.S. ETF could benefit if international economies grow steadily, consumer spending remains healthy, and demand for technology and healthcare products boosts companies like TSMC, SAP, Roche, and Novartis. On the downside, rising interest rates, slower growth in Europe or Asia, currency swings, or stricter regulations on tech, healthcare, or consumer companies such as Unilever and L’Oreal could weigh on future returns.
QLTI Top 10 Holdings
QLTI leans heavily on international blue chips, with semiconductor leaders TSMC and ASML acting as the main engines of growth thanks to their strong, if sometimes choppy, momentum. European software giant SAP has been rising lately, giving the tech sleeve extra lift, while travel-tech player Amadeus is more mixed and occasionally taps the brakes. On the defensive side, consumer staples like Unilever and Inditex, along with healthcare names Roche and Novartis, provide steady ballast. Overall, it’s a global ex-U.S. quality play, tilted toward tech and healthcare but broadly diversified.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 ES:ITX | Inditex | 5.13% | $14.87M | EUR 187.18B | 20.57% | 78Outperform |
 TSM | TSMC | 4.93% | $14.29M | $1.80T | 41.96% | 81Outperform |
 SAP | SAP SE | 4.86% | $14.09M | $272.01B | -7.97% | 69Neutral |
 UL | Unilever | 4.48% | $12.98M | $141.29B | -4.25% | 73Outperform |
 RHHBY | Roche Holding | 4.13% | $11.96M | $385.22B | 39.29% | 74Outperform |
 NVS | Novartis | 4.07% | $11.79M | $295.79B | 22.85% | 80Outperform |
 LRLCY | L'Oreal | 3.85% | $11.16M | $262.00B | 19.83% | 71Outperform |
 ES:AMS | Amadeus IT Group S.A | 3.82% | $11.07M | EUR 24.86B | -6.88% | 61Neutral |
 AIQUY | Air Liquide | 3.57% | $10.34M | $134.53B | 17.88% | 75Outperform |
QLTI Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For QLTI, the sentiment is Positive. The current price of 28.50 is above the 20-day moving average (MA) of 27.93, above the 50-day MA of 27.27, and above the 200-day MA of 26.79, indicating a bullish trend. The MACD of 0.34 indicates Negative momentum. The RSI at 62.87 is Neutral, neither overbought nor oversold. The STOCH value of 79.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QLTI.
QLTI Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| QLTI | $28.50 | $28.00(-1.75% Downside) | $289.87M | 0.60% | 61Neutral |
 JDVI | $39.40 | $45.77(16.17% Upside) | $809.64M | 0.69% | 62Neutral |
 BRIE | $30.08 | $39.36(30.86% Upside) | $794.40M | 0.34% | 64Neutral |
 OSEA | $30.10 | $36.86(22.44% Upside) | $375.37M | 0.55% | 71Outperform |
 BAIV | $28.86 | $31.82(10.23% Upside) | $196.93M | 0.60% | 60Neutral |
 IDYN | $29.99 | $34.80(16.03% Upside) | $112.98M | 0.46% | 59Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| QLTI | GMO International Quality ETF | 28.50 | 2.76 | 10.71% | |
| JDVI | John Hancock Disciplined Value International Select ETF | 39.40 | 5.42 | 15.96% | |
| BRIE | MFS Blended Research International Equity ETF | 30.07 | 4.59 | 18.03% | |
| OSEA | Harbor International Compounders ETF | 30.10 | 0.19 | 0.64% | |
| BAIV | Brown Advisory International Value Select ETF | 28.86 | 3.28 | 12.81% | |
| IDYN | iShares International Equity Factor Rotation Active ETF | 29.99 | 3.02 | 11.21% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.